1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/19/2024 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 307.24% | Baird | Joel Beatty | $11 → $9 | Maintains | Outperform | Get Alert |
03/19/2024 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 216.74% | HC Wainwright & Co. | Swayampakula Ramakanth | → $7 | Reiterates | Buy → Buy | Get Alert |
11/20/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 442.99% | Mizuho | Mara Goldstein | $20 → $12 | Maintains | Buy | Get Alert |
11/14/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 691.86% | Raymond James | Steven Seedhouse | $18.5 → $17.5 | Maintains | Outperform | Get Alert |
08/15/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 804.98% | Baird | Joel Beatty | $30 → $20 | Maintains | Outperform | Get Alert |
08/15/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 216.74% | HC Wainwright & Co. | Swayampakula Ramakanth | $2.5 → $7 | Maintains | Buy | Get Alert |
07/13/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 737.1% | Raymond James | Steven Seedhouse | $17 → $18.5 | Maintains | Outperform | Get Alert |
06/23/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 669.23% | Raymond James | Steven Seedhouse | $20 → $17 | Maintains | Outperform | Get Alert |
05/16/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 13.12% | HC Wainwright & Co. | Swayampakula Ramakanth | → $25 | Reiterates | Buy → Buy | Get Alert |
04/13/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | -9.5% | Mizuho | Mara Goldstein | → $20 | Reiterates | → Buy | Get Alert |
03/27/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 13.12% | HC Wainwright & Co. | Swayampakula Ramakanth | → $25 | Reiterates | → Buy | Get Alert |
03/27/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | -9.5% | Raymond James | Steven Seedhouse | $25 → $20 | Maintains | Outperform | Get Alert |
03/17/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | -9.5% | Mizuho | Mara Goldstein | $30 → $20 | Maintains | Buy | Get Alert |
01/27/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 35.75% | Mizuho | Mara Goldstein | $60 → $30 | Maintains | Buy | Get Alert |
01/18/2023 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 13.12% | HC Wainwright & Co. | Swayampakula Ramakanth | $40 → $25 | Maintains | Buy | Get Alert |
11/11/2022 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 13.12% | Raymond James | Steven Seedhouse | $35 → $25 | Maintains | Outperform | Get Alert |
08/15/2022 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 58.37% | Raymond James | Steven Seedhouse | $30 → $35 | Maintains | Outperform | Get Alert |
07/13/2022 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 35.75% | Raymond James | Steven Seedhouse | $40 → $30 | Maintains | Outperform | Get Alert |
10/04/2021 | LPTX | Buy Now | Leap Therapeutics | $2.21 | 171.49% | Mizuho | Mara Goldstein | — | Initiates | → Buy | Get Alert |
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on March 19, 2024. The analyst firm set a price target for $9.00 expecting LPTX to rise to within 12 months (a possible 307.24% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Leap Therapeutics (NASDAQ: LPTX) was provided by Baird, and Leap Therapeutics maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a maintained with a price target of $11.00 to $9.00. The current price Leap Therapeutics (LPTX) is trading at is $2.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.